Reference

Last reviewed: 29 Apr 2026
Sources cited: 10

Compound class639.79 Da (free base)

Synthetic mitochondria-targeted tetrapeptide — cardiolipin-binding peptide

4-residue peptide with a D-arginine at position 1 and an unnatural dimethyltyrosine (Dmt) at position 2: D-Arg-Dmt-Lys-Phe-NH₂. Contains non-natural amino acids and C-terminal amidation; the standard 3-letter sequence parser handles linear natural-amino-acid peptides only, hence the fallback.

SS-31 (Elamipretide)

Last verified: 2026-04-29

At a glance


Also known as	Elamipretide, MTP-131, Bendavia, Forzinity (US brand name, post-2025 FDA approval)
Class	Synthetic mitochondria-targeted tetrapeptide; cardiolipin-binding peptide
Typical route	Subcutaneous injection, daily
Half-life	~3–4 hours plasma; mitochondrial accumulation persists longer through cardiolipin binding
Molecular weight	639.79 Da (free base)
Sequence / structure	D-Arg-Dmt-Lys-Phe-NH₂ (4 amino acids — contains a D-arginine and an unnatural dimethyltyrosine; cell-permeable through positive-charge shielding by aromatic-ring electrons)
UK status	Not approved as a UK-licensed medicine. Sold as a research chemical.
US status	FDA-approved as Forzinity (September 2025) for Barth syndrome — a rare genetic mitochondrial disorder — in adult and paediatric patients weighing ≥30 kg. Off-label use in other indications is at prescriber discretion.5

What it is

SS-31 is the encyclopedia compound that most directly and selectively targets mitochondrial inner-membrane function. It’s a four-amino-acid synthetic peptide that accumulates 1,000–5,000-fold in the inner mitochondrial membrane through a cardiolipin-binding mechanism, then stabilises mitochondrial cristae structure, reduces oxidative stress, and enhances ATP production.

The compound was developed by Stealth BioTherapeutics (Boston-based) over a 20-year clinical development arc. It received FDA accelerated approval in September 2025 as Forzinity for Barth syndrome — a rare X-linked genetic disorder of cardiolipin metabolism caused by mutations in the TAFAZZIN gene. This is the same fundamental biology SS-31 targets: cardiolipin-deficient mitochondria fail; SS-31 stabilises them.

The biohacker / longevity community uses synthetic SS-31 for mitochondrial support in age-related conditions — particularly users with documented mitochondrial dysfunction (chronic fatigue / ME/CFS profiles), age-related macular degeneration (AMD) interest, or general longevity-focused mitochondrial optimisation. Stealth BioTherapeutics is currently in Phase 3 trials for dry AMD (the ReNEW study, expected 2026 readout); the AMD population is large (millions globally) and the biohacker AMD use case follows the trial pipeline.

This is the only compound in this encyclopedia’s mitochondrial / longevity cluster that is directly mitochondria-targeted at the molecular level — MOTS-c is endogenous mitochondrial-derived; NAD+ and NMN feed mitochondrial substrates; methylene blue functions as an alternative electron carrier; SS-31 binds and stabilises the membrane structure itself. The mechanism is the most precisely defined of any mitochondrial-targeted peptide.

Mechanism

SS-31 selectively targets the inner mitochondrial membrane through binding to cardiolipin, a unique phospholipid found almost exclusively there.1 3

The mechanistic cascade:

Cardiolipin binding — electrostatic attraction between SS-31’s positively charged D-Arg and Lys residues and cardiolipin’s negatively charged head groups
Mitochondrial accumulation — 1,000–5,000-fold concentration in the inner membrane vs cytoplasm
Cristae stabilisation — cardiolipin is essential for cristae structure; SS-31 binding stabilises this geometry
Electron transport chain optimisation — assembly of cardiolipin-dependent ETC supercomplexes (complexes I, III, IV) is preserved
Reduced ROS production — stabilised electron transport reduces electron leakage and free radical generation
Enhanced ATP production — mitochondria with intact cristae and ETC produce ATP more efficiently
Cytochrome c release prevention — cardiolipin oxidation triggers apoptotic cytochrome c release; SS-31 protects against this

The four-residue structure is genuinely unusual:

D-Arg at position 1 — D-amino acid resists peptidase degradation
Dimethyltyrosine (Dmt) at position 2 — antioxidant function; protects against tyrosine oxidation
Lys at position 3 — adds positive charge for cardiolipin binding
Phe at position 4 — completes the peptide; aromatic ring contributes to membrane permeability through positive-charge shielding by π-orbital electrons

The positive-charge shielding mechanism is mechanistically interesting. Most cationic peptides (which SS-31 effectively is, with two positive charges) struggle to cross cell membranes because the charges interact unfavourably with hydrophobic membrane interiors. SS-31’s aromatic phenylalanine and dimethyltyrosine residues shield the positive charges through π-orbital electron donation, allowing the peptide to cross both the plasma membrane and the outer mitochondrial membrane and reach the inner mitochondrial target.

The mechanism explains why SS-31 is more selective and efficient than non-targeted mitochondrial antioxidants — it accumulates where mitochondrial damage is occurring rather than diffusing throughout the cell.

Routes of administration

Subcutaneous injection (the standard and approved route)


Bioavailability	Sufficient for the documented mitochondrial effects
Onset	Mitochondrial accumulation occurs within hours; functional effects accumulate over weeks
Duration	Daily subQ dosing maintains tissue mitochondrial accumulation
Approved dose (Forzinity)	40 mg subQ once daily for adults and paediatric patients ≥30 kg
Typical biohacker dose	5–20 mg subQ daily, often cycled
Equipment (Forzinity)	Pharmaceutical autoinjector, supplied by prescription
Equipment (research-chem)	Insulin syringe (29G–31G, U-100), bacteriostatic water, alcohol wipes
When this route makes sense	Default and standard. All clinical trial data uses subQ.

The Barth syndrome dose (40 mg subQ daily) reflects a chronic disease population and an FDA-approved protocol. Biohacker dosing typically runs much lower because the compound is being used adjunctively rather than as monotherapy for a defined disease.

Intravenous (clinical trial / acute use)

IV elamipretide has been used in some clinical trials (heart failure, others). Not the typical biohacker pattern; subQ handles community use cases.

Oral, sublingual, intranasal

Not viable. SS-31’s positive charges and 4-residue structure make oral absorption unreliable and intranasal absorption insufficient for therapeutic effect.

Cross-route comparison

SubQ daily is the only meaningful route. All clinical evidence and community use is subQ.

What the evidence says

Honest summary: SS-31 has the most precisely defined mitochondrial-targeting mechanism of any compound in this encyclopedia. The clinical evidence is strongest in Barth syndrome (FDA-approved, Phase 2/3 trials with long-term extension data) and emerging in age-related macular degeneration (Phase 3 trial with 2026 readout expected). Heart failure trials failed. Off-label use in healthy biohackers is mechanistically supported but not directly studied.

Barth syndrome (FDA-approved indication)

The pivotal evidence:5 7

TAZPOWER Phase 2/3 trial — randomised double-blind placebo-controlled, 28-week active phase plus open-label extension
168-week extension data: 8 patients reached the week 168 visit; significant improvements from baseline on 6-minute walk test (cumulative 96.1 m improvement, P = .003)
September 2025 FDA accelerated approval as Forzinity: indicated to improve muscle strength in adult and paediatric patients ≥30 kg

Barth syndrome is the clearest mechanistic match for SS-31 — patients have impaired cardiolipin remodelling (TAFAZZIN mutation), and SS-31’s mechanism directly addresses the resulting mitochondrial dysfunction.

The retinal pigment epithelium has high mitochondrial density and AMD has a documented mitochondrial dysfunction component:

ReCLAIM-1 Phase 1: positive signals in geographic atrophy progression
ReCLAIM-2 Phase 2: primary endpoint not met but secondary endpoint (ellipsoid zone preservation — a marker of photoreceptor health) was significant; this surrogate endpoint became the primary for Phase 3
ReNEW Phase 3: ongoing in dry AMD; 50% enrollment achieved late 2025; readout expected 202610

If the ReNEW Phase 3 reads positive, SS-31 would be the first FDA-approved drug for the ~10 million Americans with dry AMD — a much larger market than Barth syndrome.

Heart failure (failed)

Multiple trials in heart failure populations did not meet efficacy endpoints. Despite strong preclinical signals, the clinical translation didn’t hold. Stealth BioTherapeutics shifted focus to mitochondrial-disease-specific indications and AMD.

Other clinical signals (mixed / limited)

Smaller trials and case reports have explored:

Kidney disease / acute kidney injury — promising preclinical, limited human evidence
Mitochondrial diseases beyond Barth — case reports and compassionate-use experience
Age-related muscle dysfunction — preclinical signals; not directly studied in healthy adults

Safety profile

Across the trial portfolio:

Most common AE: mild injection-site reactions (15–20% of participants)
Generally well-tolerated at the studied doses (40 mg/day in Barth syndrome; lower in earlier trials)
No major organ toxicity signals

What the evidence does NOT show

Cognitive enhancement or anti-ageing outcomes in healthy adults
Heart failure benefit — direct trials failed
Long-term safety beyond Barth syndrome trial extensions (~3 years) in any other population
Comparison data vs MOTS-c, methylene blue, NAD+ precursors at controlled levels

Typical use patterns

Approved use (Barth syndrome, prescribed Forzinity)

The FDA-approved protocol:

40 mg subQ once daily for adults and paediatric patients ≥30 kg
Continuous daily dosing
Indefinite duration (this is a chronic disease management drug)
Dispensed through specialty pharmacies under specialist supervision

Off-label biohacker / longevity protocol

Community use varies:

Standard cognitive / mitochondrial cycle: 5–10 mg subQ daily for 4 weeks; cycles every 3 months
AMD-focused use: 10–20 mg subQ daily, longer-term cycling (8–12 weeks on, 4–8 weeks off), often guided by ophthalmologist input or imaging surveillance
ME/CFS / chronic fatigue protocols: 5–10 mg subQ daily, often combined with other mitochondrial support; effects assessed over 8–12 weeks

Sensitive-start protocol

For users new to SS-31 or with reactive systems:

2.5–5 mg subQ daily for 1–2 weeks
Hold and assess for tolerance before increasing
Many sensitive users find sub-10 mg sufficient

Stacking

NAD+ axis (NAD+ IV, NMN, NR) — common pairing; mechanistically complementary (SS-31 stabilises mitochondrial structure; NAD+ precursors feed mitochondrial substrate)
Methylene blue — mechanistically complementary (different mitochondrial targets)
MOTS-c — common pairing in mitochondrial-focused stacks
CoQ10, alpha-lipoic acid, PQQ — supplemental mitochondrial-support stack additions
5-Amino-1MQ — mechanistically distinct (NNMT inhibition vs cardiolipin binding); some users combine
GH cluster — sometimes paired for sleep architecture / recovery support
No documented direct interactions with peptides or GLP-1 agonists

Why a user would choose SS-31

Most precisely-targeted mitochondrial peptide in this encyclopedia
FDA-approved (in 2025) — meaningful regulatory legitimacy
Active clinical pipeline (Phase 3 AMD trial reading 2026) — evidence base is growing
Mechanistically defensible for users with documented mitochondrial dysfunction

Why a user might be cautious

Heart failure trials failed — preclinical-to-clinical translation has been mixed
Cost — pharmaceutical Forzinity is among the most expensive drugs ever; research-chem version is much cheaper but not the same product
Off-label use in healthy adults is uncharacterised
Long-term safety beyond ~3 years not characterised in any population

For sensitive systems

SS-31’s profile in sensitive-systems users is favourable in the mitochondrial-support framework:

Mitochondrial dysfunction is a documented feature of many chronic-illness profiles
The compound’s selectivity for the inner mitochondrial membrane reduces off-target effects
The safety database (extensive Phase 1–3 trials) is the strongest of any compound in this encyclopedia’s mitochondrial cluster

Start dose for sensitive users. 2.5–5 mg subQ daily for 2 weeks. Hold before considering an increase. The compound has minimal documented systemic effects beyond the targeted mitochondrial action, but sensitive-start dosing is precautionary.

Ramp. If 5 mg is well tolerated, 10 mg is the standard biohacker target. The 40 mg approved Barth syndrome dose is appropriate for that disease but is not necessary for off-label biohacker use.

Expected adjustment profile:

Injection-site reactions — pain, redness, mild swelling. Most common AE; 15–20% of trial participants.
Mild GI symptoms — uncommon but reported
Mild fatigue — uncommon, particularly in early dosing
Subjective energy / cognitive changes — variable; some users report subtle improvements in 2–4 weeks, others report nothing

What’s not normal and warrants stopping: severe injection-site reactions, persistent fatigue not resolving, atypical chest sensations (the failed heart-failure trials don’t suggest specific cardiac harm but caution warranted), unusual symptoms persisting beyond initial adjustment.

For MCAS / histamine-sensitive users. No specific histamine activity documented. The mechanism (mitochondrial inner-membrane targeting) is not directly mast-cell-relevant. Most users in this population tolerate the compound; outliers exist.

For POTS users. No documented direct cardiovascular contraindication. Worth specific consideration: many POTS users have documented mitochondrial dysfunction components, and SS-31 is mechanistically targeted at exactly this. Some POTS users report meaningful subjective improvements over 8–12 week cycles.

For UARS / chronic fatigue / ME/CFS. The most plausible target audience for this compound. Mitochondrial dysfunction is well-documented in many ME/CFS profiles, and SS-31’s mechanism is more precisely targeted than methylene blue or NAD+ precursors. Worth a 4–8 week trial with sensitive-start dosing, careful monitoring, and ideally practitioner supervision for users with severe ME/CFS where any new compound carries flare risk.

For age-related macular degeneration (AMD) or risk thereof. Direct mechanistic relevance. Worth discussing with ophthalmologist before self-administering, particularly given the active Phase 3 trial pipeline that may produce a clear regulatory pathway in 2026.

For active or recent cancer history. SS-31’s effect on mitochondrial function in cancer cells is not well-characterised. Some cancers depend on mitochondrial metabolism (oxidative phosphorylation cancers); others rely more on glycolysis (Warburg-effect cancers). The implications for cancer survivors are uncharacterised. Get oncology input.

For pregnancy and breastfeeding. Limited safety data; FDA labelling for Forzinity advises against use without specific clinical justification.

Interactions worth considering:

Other mitochondrial-targeted compounds (methylene blue, CoQ10, MOTS-c) — mechanistically complementary; safe to combine
NAD+ precursors — mechanistically complementary; common pairing
No documented direct drug interactions at therapeutic doses
Standard medications affecting mitochondrial function (some statins, certain antibiotics) — theoretical interactions; not directly studied

Reasonable expectations

Onset. Mitochondrial accumulation occurs within hours of dosing. Functional effects accumulate over weeks to months. Subjective cognitive or energy changes, where present, typically appear in the second or third week of consistent dosing.

Response rate. In Barth syndrome trials, a meaningful proportion of patients showed measurable improvement in 6-minute walk test outcomes. In healthy biohacker populations, response rates are not directly characterised.

What the evidence actually supports.

Mitochondrial-targeted accumulation via cardiolipin binding — strongly supported preclinically and through the clinical-trial efficacy in Barth syndrome
Improved muscle function in Barth syndrome — strongly supported (FDA approval basis)
Possible benefit in dry AMD — Phase 3 ReNEW trial pending; emerging signal in earlier-phase trials
Generally well-tolerated safety profile — strongly supported through Phase 1–3 portfolio

What the evidence does not support.

Heart failure benefit — direct trials failed
Cognitive enhancement in healthy adults — not directly studied
Anti-ageing or longevity claims at the lifespan-extension level — speculative
Body composition or athletic performance outcomes — not the studied indication

What not to expect.

Acute single-dose effects. The compound’s effects build over weeks.
Reliable cognitive enhancement in users without mitochondrial dysfunction. The mechanism targets dysfunctional mitochondria; in users with healthy mitochondria, the marginal benefit may be small or undetectable.
Cure for chronic mitochondrial diseases. SS-31 is FDA-approved as a maintenance treatment for Barth syndrome, not a cure.

Cost

Pharmaceutical Forzinity (US, post-2025 FDA approval)

Forzinity is a specialty drug for a rare disease:

Industry analyst estimates: $50,000–$80,000 per year of treatment, comparable to other orphan-drug pricing
Insurance coverage variable; manufacturer assistance programs exist for the licensed indication
Off-label prescribing for AMD, ME/CFS, or other conditions is at prescriber discretion and unlikely to be insurance-covered

Research-chemical SS-31 (UK and US)

The research-chem path is the dominant biohacker access route:

10 mg vials: ~£40–100 / $50–125
20 mg vials: ~£70–180 / $90–220
30 mg vials: ~£100–250 / $130–320

Monthly cost at 10 mg/day, 5 days/week: roughly £60–180/month, mid-to-upper range for compounds in this encyclopedia.

The cost gap between pharmaceutical Forzinity and research-chem SS-31 is the largest of any compound in this encyclopedia (~100× to 1,000× depending on dose and source).

Quality variance

SS-31’s 4-residue structure with unnatural amino acids (D-Arg, Dmt) makes synthesis quality more variable than for shorter peptides. Lab-tested vendors with mass-spec or HPLC certificates are essential — improperly synthesised SS-31 may lack the cardiolipin-binding activity that drives the mechanism.

Sensitive-start economics

A user starting at 2.5 mg/day uses one-quarter of the standard 10 mg dose. A 10 mg vial covers ~40 doses, well past the reconstituted shelf life — buy smaller vials or accept significant product loss for low-dose protocols.

Reconstitution

What’s in the box

Research-chemical SS-31 ships as lyophilised white powder in a glass vial, typically 10 mg, 20 mg, or 30 mg per vial.

You’ll also need: BAC water, U-100 insulin syringe, larger transfer syringe, alcohol wipes.

The math

10 mg vial, 1 mL BAC water (the standard for community dosing)

Concentration: 10 mg/mL (10,000 mcg/mL)
2.5 mg sensitive-start = 0.25 mL = 25 units
5 mg = 0.5 mL = 50 units
10 mg = 1 mL = 100 units (full single-syringe range)

10 mg vial, 2 mL BAC water (for users wanting smaller draws)

Concentration: 5 mg/mL (5,000 mcg/mL)
2.5 mg = 0.5 mL = 50 units
5 mg = 1 mL = 100 units

30 mg vial, 3 mL BAC water (for higher-dose protocols)

Concentration: 10 mg/mL
10 mg = 1 mL = 100 units
20 mg = 2 mL = 200 units (over a single 100-unit syringe; consider denser reconstitution or split injection)
40 mg (Forzinity-equivalent) = 4 mL — impractical at this concentration; reconstitute with less BAC

The Peptrax Vial Plan calculator handles the same math interactively.

Reconstitution procedure

Same as the rest of the encyclopedia: alcohol-wipe stoppers, slow water injection down the vial side, no shaking, label vial, refrigerate.

Storage and stability

SS-31 reconstituted with BAC water is stable for ~28 days refrigerated — at the standard end of the research-chem peptide range.

Conservative: 14–21 days
Middle: 28 days
Optimistic: 30 days

Store at the back of the refrigerator. Do not freeze.

If you reconstitute with plain sterile water, the vial is single-use — discard within 24 hours.

For a 10 mg vial at 5 mg/day: 2 doses → 2 days, well within shelf life. For a 30 mg vial at 5 mg/day: 6 doses → 6 days, comfortably within stability.

What gets miscalculated

mg vs mcg confusion — SS-31 doses are in mg
Reading “units” as mg — units are a volume mark
Dosing at the Forzinity 40 mg level for off-label use — the approved dose is for Barth syndrome chronic management; biohacker dosing typically runs much lower
Skipping cycling and assuming continuous dosing is safe — long-term off-label use is not characterised

Areas of concern ⚠

Off-label evidence gap (despite the FDA approval)

The FDA-approved indication is Barth syndrome — a rare genetic disorder. Off-label use in:

AMD (Phase 3 ongoing; readout 2026)
Heart failure (failed trials)
Cognitive enhancement / anti-ageing (not directly studied in healthy adults)

The mechanism is plausible across mitochondrial dysfunction contexts, but the evidence base for off-label use varies dramatically by indication.

Long-term safety beyond ~3 years uncharacterised

The longest controlled human trial is the TAZPOWER 168-week extension in Barth syndrome. Multi-year safety in other populations (especially healthy biohackers) is not characterised. The Barth syndrome population is small and selected; generalisability to off-label use is mechanistically defensible but not directly demonstrated.

Heart failure trials failed

Despite strong preclinical signals, heart failure clinical trials did not meet efficacy endpoints. This is mechanistically interesting — SS-31 should help dysfunctional cardiac mitochondria — but the clinical translation didn’t hold. Users considering SS-31 for cardiac applications should treat the failed trials as the relevant evidence, not the mechanism alone.

Quality and sourcing — variance higher than typical

SS-31’s complexity (D-amino acids, Dmt) makes synthesis quality variable in the research-chem market. Lab-tested vendors with explicit mass-spec or HPLC certificates are essential. Substituted or improperly synthesised SS-31 may be functionally inactive — in which case users pay for nothing meaningful.

The pharmaceutical product (Forzinity) has supply-chain integrity that research-chem product cannot match. For users with serious health concerns who are considering SS-31 specifically for the documented mechanism, the access path matters.

Cost-benefit for healthy users

The compound is among the more expensive in this encyclopedia for off-label use, with limited evidence for benefit in healthy adults. The cost-benefit calculation favours users with documented mitochondrial dysfunction (ME/CFS, mitochondrial disease, AMD risk) over healthy users with general longevity interest.

Populations where SS-31 is contraindicated or high-risk

Active or recent cancer history (relative contraindication; oncology input needed for the cardiolipin-binding mechanism’s cancer-relevant implications)
Pregnancy and breastfeeding — limited safety data
Severe injection-site reactions historically — caution
Under 18 (off-label) — Forzinity is approved for paediatric patients ≥30 kg in Barth syndrome but not for off-label use
Severe immunocompromise — uncharacterised in this population

Measurement and dosing pitfalls

mg vs mcg confusion
Dosing at Forzinity 40 mg/day off-label — appropriate for Barth syndrome; not necessary for biohacker use
Treating SS-31 as a peptide-stack substitute — the mechanism is specifically mitochondrial; users without mitochondrial dysfunction get less benefit
Quality assumptions on cheap research-chem product — synthesis variance is real

What the community gets wrong

“FDA-approved means it works for everything mitochondrial.” It’s approved for Barth syndrome. The AMD evidence is emerging; heart failure evidence is negative; biohacker use is extrapolated.
“Anti-ageing peptide.” Mechanistically plausible; not directly supported by trials in healthy adults.
“Replacement for NAD+ stack.” Mechanistically distinct (cardiolipin binding vs NAD+ supply). Complementary, not substitutive.
“Same as MOTS-c.” Both are mitochondrial peptides, but MOTS-c is endogenous and acts via different pathways.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Approved as Forzinity (September 2025) for Barth syndrome in adult and paediatric patients ≥30 kg.5 Off-label use is at prescriber discretion.	2026-04-29
UK (MHRA)	Not approved as a UK-licensed medicine. No NHS or private-prescription pathway. Sold as a research chemical.	2026-04-29
EU (EMA)	Not centrally approved by EMA.	2026-04-29
WADA (sport)	Not specifically prohibited as of the 2026 list.	2026-04-29

Narrative. SS-31 is the encyclopedia compound with the most recent and narrow FDA approval pathway. The Barth syndrome indication is rare; the AMD Phase 3 trial pipeline (ReNEW, expected 2026 readout) may produce a much broader regulatory pathway. For UK readers, no licensed pathway exists in any direction; research-chem purchase is the only access route. For US readers with Barth syndrome, the licensed pathway is established but small; for off-label use, prescriber willingness varies.

What to track in Peptrax

A user dosing SS-31 for ME/CFS, an AMD-risk user dosing for retinal protection, and a longevity-focused user dosing for general optimisation are running essentially three different protocols with three different success criteria. The compound is the same; the relevant outcome measures are not. Capturing the indication first determines what the right log fields are — PEM episode tracking for ME/CFS, ophthalmology imaging for AMD, biomarker panels for longevity.

For most users, the highest-signal log is subjective energy and post-exertional response across an 8–12 week cycle. SS-31’s effects, where present, are slow and accumulative; daily 1–5 ratings provide the cleanest read. ME/CFS users specifically should log post-exertional malaise (PEM) episodes and crash duration as primary outcome measures.

For AMD-focused users, the priority log is ophthalmologist-supervised imaging (OCT, fundus photography) at baseline and 6-month intervals. The mechanism affects retinal mitochondrial function over months; subjective vision changes are unreliable surrogates.

Across all users, logging the source product matters because synthesis quality variance is real for SS-31 specifically. The pharmaceutical product (Forzinity) is the gold standard; research-chem product varies. Tracking which batch produced which response is the only way to identify quality issues.

For personal tracking and informational purposes only — not medical advice.